Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | -19.68% | +32.45% | -25.09% |
05-02 | Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding | CI |
04-30 | Top Midday Gainers | MT |
Business Summary
Number of employees: 12
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cancer Medicines
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 31/07/97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 31/12/01 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 16/12/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 28/02/06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 16/12/20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 31/07/97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 31/12/01 |
Robert Spiegel
BRD | Director/Board Member | 73 | 11/09/18 |
Samuel Barker
BRD | Director/Board Member | 81 | 10/09/14 |
Kenneth Ferguson
BRD | Director/Board Member | 68 | 13/06/22 |
Karin Walker
BRD | Director/Board Member | 60 | 08/11/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 119,000 | 0 | 0 | 68.08 % |
Stock B | 0 | 264 | 0 | 0 | |
Stock C | 1 | 1,463,257 | 1,224,417 ( 83.68 %) | 0 | |
Stock D | 0 | 335,273 | 0 | 0 |
Company contact information
Cyclacel Pharmaceuticals, Inc.
200 Connell Drive Suite 1500
07922, Berkeley Heights
+908 517 7330
http://www.cyclacel.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.09% | 2.64M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- CYCC Stock
- Company Cyclacel Pharmaceuticals, Inc.